Approval of GAVRETO™ (pralsetinib)

CAMBRIDGE, Mass., September 4, 2020 – Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that the U.S. Food and Drug Administration (FDA) has...

Cone Health Cancer Center at Wesley Long

MISSION STATEMENT/PHILOPSOPHY: Our vision is to provide an exceptional, unsurpassed health care experience at the Cone Health Cancer care program.  Our mission is to create a patient-centered, safe, high-quality, comprehensive program to meet the needs of our...